AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34854538 — intervention group
Group type: COMPARATOR
Intervention: Care as usual control group (n = 44)
Number of subjects: 93
Study 35770520 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol (1 mg, twice a day for 6 months)
Number of subjects: 137
Study 35770520 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol-metformin (500 mg metformin combined with 1 mg mazindol, twice a day for 6 months)
Number of subjects: 137
Study 33051828 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient ambassador support for 12 weeks
Number of subjects: 36
Study 35099400 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPlan 2.0 intervention
Number of subjects: 473
Study 33074074 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 10^6 conidia/ml suspension of Colletotrichum siamense
Number of subjects: 20
Study 33074074 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-inoculated Zinnia plants)
Number of subjects: 20
Study 36208293 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab (10 mg/kg intravenous)
Number of subjects: 677
Study 36208293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 677
Study 36208293 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 677
Study 35212749 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief social contact-based video intervention featuring transgender adolescent girls
Number of subjects: 1437
Study 35212749 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief social contact-based video intervention featuring transgender adolescent boys
Number of subjects: 1437
Study 35212749 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief social contact-based video intervention featuring cisgender adolescent girls
Number of subjects: 1437
Study 35212749 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief social contact-based video intervention featuring cisgender adolescent boys
Number of subjects: 1437
Study 35212749 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1437
Study 33065817 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping with Depression course with additional daily placebo treatment
Number of subjects: 126
Study 33065817 — intervention group
Group type: COMPARATOR
Intervention: Coping with Depression course
Number of subjects: 126
Study 33065817 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group
Number of subjects: 126
Study 35597959 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided digital treatment comprising psychoeducation and virtual reality exposure therapy (VRET) for 6 weeks, including one therapy session preparing for VRET and 4 weeks of self-guided VRET.
Number of subjects: 30
Study 35597959 — intervention group
Group type: COMPARATOR
Intervention: Relaxation and stress-reduction training (control group).
Number of subjects: 30
Study 33561220 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking initiated 20 minutes before the PPG peak (20iP)
Number of subjects: 20
Study 33561220 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking initiated at the PPG peak time (iP)
Number of subjects: 20
Study 33561220 — intervention group
Group type: COMPARATOR
Intervention: Sitting (SIT)
Number of subjects: 20
Study 35137068 — intervention group
Group type: EXPERIMENTAL
Intervention: CoVideo (animated video on COVID-19 prevention)
Number of subjects: 15163
Study 35137068 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control (APC) and do-nothing arms
Number of subjects: 15163
Study 34114246 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for enhancing medical record access
Number of subjects: 0
Study 32858361 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) therapy for at least three months (mean 377.6 ± 419.5 days)
Number of subjects: 1564
Study 33462817 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydraulic tomography (HT) with a randomized binary prior model
Number of subjects: 0
Study 33462817 — intervention group
Group type: COMPARATOR
Intervention: Conventional pilot-point inversion scheme
Number of subjects: 0
Study 32371401 — intervention group
Group type: EXPERIMENTAL
Intervention: LoDED strategy (limit of detection and ECG discharge)
Number of subjects: 629
Study 32371401 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 629
Study 32371401 — intervention group
Group type: EXPERIMENTAL
Intervention: LoDED strategy
Number of subjects: 629
Study 36014787 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% energy deficit diet and training (online intervention)
Number of subjects: 400
Study 32831874 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-Animal Frolics Exercise (FAE)
Number of subjects: 0
Study 32831874 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (Control Group)
Number of subjects: 0
Study 34510643 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-week group-based weight loss program
Number of subjects: 60
Study 34510643 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 60
Study 33483123 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) - nine sessions
Number of subjects: 80
Study 33483123 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) - nine sessions
Number of subjects: 80
Study 33483123 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 80
Study 33483123 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 80
Study 32972271 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based program (MBP) plus diet
Number of subjects: 52
Study 32972271 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (Control)
Number of subjects: 52
Study 34236101 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-Carbidopa Intestinal Gel (LCIG)
Number of subjects: 63
Study 34236101 — intervention group
Group type: COMPARATOR
Intervention: Oral Optimized Medical Treatment (OMT)
Number of subjects: 63
Study 32150258 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care intervention
Number of subjects: 222
Study 32150258 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 222
Study 36229781 — intervention group
Group type: EXPERIMENTAL
Intervention: ANRC‐Essentials Plus (ANRC‐EP)
Number of subjects: 161
Study 33405297 — intervention group
Group type: EXPERIMENTAL
Intervention: 140% Insulin-to-Carbohydrate Ratio (ICR)
Number of subjects: 27
Study 33405297 — intervention group
Group type: EXPERIMENTAL
Intervention: 160% Insulin-to-Carbohydrate Ratio (ICR)
Number of subjects: 27
Study 33405297 — intervention group
Group type: COMPARATOR
Intervention: 100% Insulin-to-Carbohydrate Ratio (ICR)
Number of subjects: 27
Study 33405297 — intervention group
Group type: EXPERIMENTAL
Intervention: 120% Insulin-to-Carbohydrate Ratio (ICR)
Number of subjects: 27
Study 33405297 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing insulin doses (100%-160% ICR)
Number of subjects: 27
Study 32437174 — intervention group
Group type: EXPERIMENTAL
Intervention: EQuIP (Empowering Queer Identities in Psychotherapy)
Number of subjects: 60
Study 32437174 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 60
Study 35984904 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 240
Study 34092093 — intervention group
Group type: EXPERIMENTAL
Intervention: DA+DCB
Number of subjects: 80
Study 34092093 — intervention group
Group type: COMPARATOR
Intervention: DCB
Number of subjects: 80
Study 32609651 — intervention group
Group type: COMPARATOR
Intervention: Placebo interventions
Number of subjects: 0
Study 32609651 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological and nonpharmacological treatments
Number of subjects: 0
Study 32609651 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' perception and verbal suggestions for pain relief
Number of subjects: 0
Study 32609651 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations toward treatment effects
Number of subjects: 0
Study 32609651 — intervention group
Group type: EXPERIMENTAL
Intervention: Unintentional unblinding and patients' perception of treatment
Number of subjects: 0
Study 36240100 — intervention group
Group type: EXPERIMENTAL
Intervention: Telestroke assessment
Number of subjects: 76
Study 36240100 — intervention group
Group type: COMPARATOR
Intervention: PASTA assessment
Number of subjects: 76
Study 32000419 — intervention group
Group type: EXPERIMENTAL
Intervention: Daesiho‐tang (DSHT)
Number of subjects: 120
Study 32000419 — intervention group
Group type: EXPERIMENTAL
Intervention: Chowiseungcheng‐tang (CST)
Number of subjects: 120
Study 32000419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 35596963 — intervention group
Group type: COMPARATOR
Intervention: Standard implementation
Number of subjects: 544
Study 35596963 — intervention group
Group type: COMPARATOR
Intervention: Enhanced implementation
Number of subjects: 544
Study 32419670 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma and the Body Group (TBG) - 20-session group psychotherapy
Number of subjects: 32
Study 32419670 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 32
Study 33259428 — intervention group
Group type: EXPERIMENTAL
Intervention: Video call
Number of subjects: 251
Study 33259428 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone call
Number of subjects: 251
Study 33259428 — intervention group
Group type: COMPARATOR
Intervention: No contact (standard of care)
Number of subjects: 251
Study 35436329 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training
Number of subjects: 103
Study 35436329 — intervention group
Group type: COMPARATOR
Intervention: Low intensity sham exercise control
Number of subjects: 103
Study 34267583 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4 (four weekly campus board training sessions)
Number of subjects: 16
Study 34267583 — intervention group
Group type: EXPERIMENTAL
Intervention: TG2 (two weekly campus board training sessions)
Number of subjects: 16
Study 34267583 — intervention group
Group type: EXPERIMENTAL
Intervention: Merged training groups
Number of subjects: 16
Study 34267583 — intervention group
Group type: COMPARATOR
Intervention: CG (control group)
Number of subjects: 16
Study 33045833 — intervention group
Group type: EXPERIMENTAL
Intervention: PDCoV-infected IPEC-J2 cells
Number of subjects: 78
Study 33045833 — intervention group
Group type: EXPERIMENTAL
Intervention: Verification of DEPs (ANAPC7 and IFIT1)
Number of subjects: 78
Study 33045833 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioinformatics analyses
Number of subjects: 78
Study 35342439 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 24
Study 35342439 — intervention group
Group type: COMPARATOR
Intervention: Adaptive Support Ventilation (ASV)
Number of subjects: 24
Study 36320825 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding methotrexate for 2 weeks after each dose of ChAdOx1 nCov‐19 vaccine (MIVAC I)
Number of subjects: 250
Study 36320825 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding methotrexate for 2 weeks after the second dose of ChAdOx1 nCov‐19 vaccine (MIVAC II)
Number of subjects: 250
Study 36320825 — intervention group
Group type: COMPARATOR
Intervention: Continuation of methotrexate
Number of subjects: 250
Study 34716893 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified 3-day weekend frequency-volume chart (FVC)
Number of subjects: 1200
Study 34716893 — intervention group
Group type: COMPARATOR
Intervention: ICCS-recommended voiding diary
Number of subjects: 1200
Study 36006791 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life simulated scenario
Number of subjects: 0
Study 35067125 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic assisted training (assisted motion, biofeedback, antagonist muscle vibration)
Number of subjects: 83
Study 35067125 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (designed to have no effect)
Number of subjects: 83
Study 33630509 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Reserve (AR) measured by staff survey
Number of subjects: 142
Study 33630509 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Capacity Assessment (QICA)
Number of subjects: 142
Study 33630509 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline AR
Number of subjects: 142
Study 33630509 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in AR
Number of subjects: 142
Study 32669306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic BP control (<120 mm Hg)
Number of subjects: 8885
Study 32669306 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic BP control (<140 mm Hg)
Number of subjects: 8885
Study 36354243 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of magnesium daily (two 250-mg magnesium oxide tablets for five days)
Number of subjects: 60
Study 36354243 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 60
Study 33736542 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation (ER) group started exercising between 24 and 48 hours after stroke onset
Number of subjects: 110
Study 33736542 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation (ER) group
Number of subjects: 110
Study 33736542 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (SR) group started exercising between 72 and 96 hours after stroke onset
Number of subjects: 110
Study 34881835 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (Rybelsus®)
Number of subjects: 9543
Study 32987642 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 168
Study 35345663 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide single agent and doxorubicin
Number of subjects: 70
Study 35345663 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide capsules (control group)
Number of subjects: 70
Study 34725095 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 0
Study 34725095 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 0
Study 36079832 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary magnesium
Number of subjects: 392
Study 36079832 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary potassium
Number of subjects: 392
Study 36079832 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary calcium
Number of subjects: 392
Study 36079832 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary phosphorus
Number of subjects: 392
Study 34495437 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic anticonvulsant use in both aSAH and sICH
Number of subjects: 103
Study 34495437 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic anticonvulsant use only in aSAH
Number of subjects: 103
Study 34495437 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic anticonvulsant use only in sICH
Number of subjects: 103
Study 34495437 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective use of ASMs in sICH
Number of subjects: 103
Study 34495437 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic anticonvulsant use for all patients with aSAH
Number of subjects: 103
Study 34495437 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (Keppra) as the most commonly used ASM
Number of subjects: 103
Study 34495437 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to randomize sICH patients to management with or without ASM prophylaxis
Number of subjects: 103
Study 34495437 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to randomize aSAH patients to management with or without ASM prophylaxis
Number of subjects: 103
Study 34495437 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct response to AHA/ASA Guidelines on prophylactic anticonvulsants in sICH
Number of subjects: 103
Study 36441106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension (EXT) intervention
Number of subjects: 175
Study 36441106 — intervention group
Group type: COMPARATOR
Intervention: Family routines support (FRS) consultation
Number of subjects: 175
Study 34382717 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of French maritime pine bark extract supplementation (Oligopin) with enteral nutrition for 10 days
Number of subjects: 67
Study 34382717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 32075663 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative package of non-operative care (weight-loss programme, exercises, advice on analgesia use, provision of insoles)
Number of subjects: 60
Study 32075663 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 33221341 — intervention group
Group type: EXPERIMENTAL
Intervention: AB2 (affinity-matured recombinant Fab inhibitor)
Number of subjects: 0
Study 33221341 — intervention group
Group type: COMPARATOR
Intervention: U33 (parental Fab)
Number of subjects: 0
Study 32828924 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-based neurofeedback during shoulder motor imagery (MI)
Number of subjects: 0
Study 32828924 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-based neurofeedback during hand motor imagery (MI)
Number of subjects: 0
Study 35137002 — intervention group
Group type: EXPERIMENTAL
Intervention: ABA10
Number of subjects: 123
Study 35137002 — intervention group
Group type: EXPERIMENTAL
Intervention: ABA30/10
Number of subjects: 123
Study 35137002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 34154445 — intervention group
Group type: EXPERIMENTAL
Intervention: ED‐ASBI without GP follow‐up
Number of subjects: 453
Study 34154445 — intervention group
Group type: COMPARATOR
Intervention: GP follow‐up
Number of subjects: 453
Study 35339185 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative susceptibility mapping (QSM)
Number of subjects: 400
Study 34292213 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural garment PosturePlusForce
Number of subjects: 32
Study 34292213 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 32
Study 33180798 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based resilience intervention (stress management and mindfulness tools), delivered in six sessions over six weeks.
Number of subjects: 430
Study 33180798 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (online stress and mental health education), delivered in six modules over six weeks.
Number of subjects: 430
Study 36411968 — intervention group
Group type: EXPERIMENTAL
Intervention: PMC split-dose regimen
Number of subjects: 0
Study 36411968 — intervention group
Group type: COMPARATOR
Intervention: PMC day-before regimen
Number of subjects: 0
Study 32644304 — intervention group
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade™
Number of subjects: 20
Study 32644304 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrosurgery
Number of subjects: 20
Study 32644304 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study 34967147 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazpiroben 50 mg
Number of subjects: 24
Study 34967147 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazpiroben 100 mg
Number of subjects: 24
Study 34967147 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazpiroben 10 mg
Number of subjects: 24
Study 34967147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 34904948 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of PRO results
Number of subjects: 227
Study 34904948 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of PRO results plus self‐management intervention
Number of subjects: 227
Study 34904948 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 227
Study 36279795 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg/kg HPβCD intravenously every 2 weeks for a total of 7 doses (14 weeks)
Number of subjects: 13
Study 36279795 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 mg/kg HPβCD intravenously every 2 weeks for a total of 7 doses (14 weeks)
Number of subjects: 13
Study 36279795 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD treatment
Number of subjects: 13
Study 34805403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 165
Study 34805403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine plus clowns
Number of subjects: 165
Study 34805403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 34805403 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus clowns
Number of subjects: 165
Study 34805403 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydroxyzine and clowns
Number of subjects: 165
Study 33402123 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive counseling (6 sessions, 45–60 minutes each)
Number of subjects: 66
Study 33402123 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 66
Study 32383736 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatar-led intervention (Flexiquit)
Number of subjects: 105
Study 32383736 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 105
Study 35193545 — intervention group
Group type: EXPERIMENTAL
Intervention: Enerisant 25 mg/day
Number of subjects: 99
Study 35193545 — intervention group
Group type: EXPERIMENTAL
Intervention: Enerisant 50 mg/day
Number of subjects: 99
Study 35193545 — intervention group
Group type: EXPERIMENTAL
Intervention: Enerisant 100 mg/day
Number of subjects: 99
Study 35193545 — intervention group
Group type: EXPERIMENTAL
Intervention: Enerisant 5 mg/day
Number of subjects: 99
Study 35193545 — intervention group
Group type: EXPERIMENTAL
Intervention: Enerisant 10 mg/day
Number of subjects: 99
Study 35193545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 33974688 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high nutrition (EHN) - milk replacer (maximum intake of 1.8 kg/d) until 3 mo, then high-concentrate diet from 4 to 10 mo
Number of subjects: 23
Study 33974688 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high nutrition (EHN)
Number of subjects: 23
Study 33974688 — intervention group
Group type: COMPARATOR
Intervention: Roughage group (RG)
Number of subjects: 23
Study 32809136 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 166